The clinical relevance of NET-mediated antifungal defense is evident in chronic granulomatous disease (CGD) patients, who have defective NADPH oxidase activity, resulting in impaired ROS production and compromised NETs release. The gene discussed is FMO5; the disease is chronic granulomatous disease.